COPDMAP
Research Areas
At a Glance
- Status: Completed Consortium
- Year Launched: 2011
- Initiating Organization: MRC/ABPI Inflammation and Immunology Initiative
- Initiator Type: Government
- Disease focus:
Copd - Location: Europe
Abstract
COPDMAP, as part of the Medical Research Council (MRC)/Association of the British Pharmaceutical Industry (ABPI) Inflammation and Immunology Initiative, represents the first phase of a new approach in funding by the MRC, bringing together academics and industry at the early research and development stages to develop a stratified approach to disease (targeting the right treatments to the right people), enabling effective clinical trials as well as identifying novel biomarkers, mechanisms, and targets.
Structure & Governance
The following are COPDMAP Work Packages (WPs):
Financing
COPDMAP is funded by MRC and ABPI as part of the Inflammation and Immunology Initiative.
Links/Social Media Feed
Homepage |
Sponsors & Partners
AstraZeneca |
GlaxoSmithKline |
Imperial College London |
King’s College Hospital |
NewCastle University |
Novartis |
Pfizer |
Royal Brompton & Harefield |
The University of Edinburgh |
The University of Manchester |
The University of Nottingham |
The University of Sheffield |
UCL (London’s Global) |
University of Birmingham |
University of Cambridge |
University of Leicester |
University of Liverpool |
University of Southampton |